Key Factors for Type 1 Diabetes Mellitus Therapeutics Market Growth 2021

1
Type 1 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021 - Innovative and
Diversified Pipeline to Drive Market Growth
Despite Patent Expirations
Published on 01 November, 2015 Number of
pages 159 Single User Price 4995
Type 1 Diabetes Mellitus (T1DM) is a chronic,
progressive and serious disease characterized by
a destruction or failure of insulin-secreting
pancreatic beta cells, usually as a result of an
autoimmune response.
2
Summary of the ReportType 1 Diabetes Mellitus
(T1DM) is a chronic, progressive and serious
disease characterized by a destruction or failure
of insulin-secreting pancreatic beta cells,
usually as a result of an autoimmune response.
The resulting insulin deficiency prevents
insulin-sensitive cells from carrying out
essential glucose metabolism and leads to
hyperglycemia (high blood glucose levels). As a
result, immediate and lifelong treatment with
exogenous insulin therapy is initiated upon
diagnosis of T1DM. Exogenous insulin has remained
the mainstay of T1DM therapy since it was used to
treat the first human patient in
1922. Consequently, insulin products comprise
the vast majority of the T1DM market, which is
largely monopolized by three big pharma players
Eli Lilly, Novo Nordisk and Sanofi. However,
insulin treatment regimens are often inconvenient
and are associated with undesirable side effects
such as hypoglycemia (low blood glucose levels)
and weight gain. In addition, there is a
significant unmet need for more diversified
treatment options including therapies capable of
altering the clinical course of the pathological
beta cell destruction and adjuvant therapies
capable of improving glycemic control and
reducing insulin requirements.
Click Here To Check Complete Report
3

• Scope of the Report
• The report assesses the current T1DM market and
  forecasts market trends to 2021. Areas covered
  include
• An introduction to T1DM, which includes
  classification, symptoms, etiology,
  pathophysiology, co-morbidities and
  complications, diagnosis and treatment
• An analysis of the leading insulin therapies in
  the current T1DM marketed products landscape.
• An analysis of the pipeline for T1DM. This
  includes a breakdown of pipeline molecules by
  stage of development, molecule type, route of
  administration, molecular target and novelty.
  Trends in T1DM clinical trial size, duration and
  failure rates, by molecule type and molecular
  target are discussed. A comparative analysis of
  the most promising pipeline molecules is also
  provided.
• Forecast projections for the T1DM market to 2021.
  An analysis is provided for the global market and
  each of the eight major markets. The forecast
  incorporates projected, low and high variance
  scenarios based on treatment usage patterns and
  annual therapy costs in each of the major
  markets.
• An analysis of strategic consolidations,
  including co-development and licensing deals,
  within the T1DM indication.

Download Sample Brochure
4

• Reasons to buy
• The report will provide clients with a strong
  understanding of the T1DM indication and an
  appreciation of the evolving landscape of the
  T1DM therapeutics market. The report will enable
  clients to -
• Appreciate the current T1DM marketed products
  landscape, including the dominant therapeutic
  strategies, products, and companies, and
  recognize gaps within the market and areas of
  unmet need
• Identify trends and developments within the T1DM
  pipeline and consider how the future competitive
  environment will be impacted.
• Consider market opportunities and potential risks
  by examining trends in T1DM clinical trial
  duration and size, as well as clinical trial
  failure rates, amongst clinical phases and
  molecule types
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  on the T1DM therapeutics market
• Understand how strategic consolidations have
  shaped the current T1DM pipeline and marketed
  products landscapes

Make an Inquiry Before Buying
5
Type 1 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021 - Innovative and
Diversified Pipeline to Drive Market Growth
Despite Patent Expirations
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Type 1 Diabetes Mellitus Therapeutics Market
are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Type 1 Diabetes
Mellitus Therapeutics Market Report